Standard BioTools (LAB) SEC Filings: History & Chart

Standard BioTools Inc.(LAB)

Medical - Specialties · Boston, MA

$0.73-0.03 (-3.79%)

Delayed quote: Oct 6, 2026, 1:55 PM EDT

About Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Boston, MA

387 employees

www.standardbio.com

Healthcare / Medical - Specialties

Sector: Healthcare
Industry: Medical - Specialties
CEO: Michael Egholm

View full financials

Form	Filing Date	Accepted	Document
425	Oct 5, 2026	Oct 5, 2026	View filing
8-K	Oct 5, 2026	Oct 5, 2026	View filing
425	Sep 30, 2026	Sep 30, 2026	View filing
8-K	Sep 30, 2026	Sep 30, 2026	View filing
S-4/A	Sep 9, 2026	Sep 9, 2026	View filing
4	Aug 24, 2026	Aug 24, 2026	View filing
4	Aug 24, 2026	Aug 24, 2026	View filing
4	Aug 24, 2026	Aug 24, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G	Aug 14, 2026	Aug 14, 2026	View filing
S-8	Aug 5, 2026	Aug 5, 2026	View filing
S-8	Aug 5, 2026	Aug 5, 2026	View filing
10-Q	Aug 5, 2026	Aug 5, 2026	View filing
8-K	Aug 5, 2026	Aug 5, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
SC 13G/A	Jul 30, 2026	Jul 30, 2026	View filing
425	Jul 29, 2026	Jul 29, 2026	View filing
8-K/A	Jul 29, 2026	Jul 29, 2026	View filing
425	Jul 28, 2026	Jul 28, 2026	View filing
425	Jul 28, 2026	Jul 28, 2026	View filing
8-K	Jul 28, 2026	Jul 28, 2026	View filing
4	Jul 27, 2026	Jul 27, 2026	View filing
8-K	Jul 24, 2026	Jul 24, 2026	View filing
425	Jul 20, 2026	Jul 20, 2026	View filing
S-4	Jul 20, 2026	Jul 20, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing

SEC Filings

Recent Filings